Skip to main content
Premium Trial:

Request an Annual Quote

American Cancer Society Philanthropic Fund BrightEdge Invests in Castle Bio

NEW YORK (GenomeWeb) — The American Cancer Society's (ACS) newly formed philanthropic fund BrightEdge has made its first investment, contributing $3 million to Castle Biosciences' $11.6 million convertible note financing last month, the organizations said on Thursday.

BrightEdge, headquartered in Atlanta, was founded by the ACS to invest in for-profit companies developing novel cancer therapeutics and diagnostics. It was established with a $25 million commitment from ACS and aims to raise an additional $100 million from private donors.

Friendswood, Texas-based Castle Bio develops and markets genetic tests for skin cancer including its flagship DecisionDx-Melanoma assay, an RT-PCR-based test gene expression profile test designed to identify high-risk stage I and II cutaneous melanoma patients.

"The significance of this investment goes well beyond simply representing BrightEdge’s first deal," BrightEdge Managing Director Bob Crutchfield said in a statement. "Castle Biosciences … has potential to deliver a strong financial return and moves us forward in BrightEdge's ultimate mission to drive innovation and win the fight against cancer."

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.